特别关注｜PD-1/PD-L1在肝细胞癌治疗中的应用(14)

[19]ZHU AX, FINN RS, IKEDA M, et al. A phase Ib study of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC)[J]. J Clin Oncol, 2020, 38(15 Suppl): 4519.
[20]LLOVET JM, KUDO M, CHENG AL, et al. Lenvatinib (len) plus pembrolizumab (pembro) for the first-line treatment of patients (pts) with advanced hepatocellular carcinoma (HCC): Phase 3 LEAP-002 study[J]. J Clini Oncol, 2019, 37(15 Suppl): TPS4152.
[21]KUDO M, IKEDA M, MOTOMURA K, et al. A phase Ib study of lenvatinib (LEN) plus nivolumab (NIV) in patients (pts) with unresectable hepatocellular carcinoma (uHCC): Study 117[J]. J Clin Oncol, 2020, 38(4 Suppl): 513.
[22]XU J, ZHANG Y, JIA R, et al. Anti-PD-1 antibody SHR-1210 combined with apatinib for advanced hepatocellular carcinoma, gastric, or esophagogastric junction cancer: An open-label, dose escalation and expansion study[J]. Clin Cancer Res, 2019, 25(2): 515-523. DOI: 10.1158/1078-0432.CCR-18-2484
[23]KUDO M, MOTOMURA K, WADA Y, et al. First-line avelumab axitinib in patients with advanced hepatocellular carcinoma: Results from a phase 1b trial (VEGF Liver 100)[J]. J Clin Oncol, 2019, 37(15 Suppl): 4072.